Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 21, 2024, BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 189,775,040 shares of common stock were entitled to vote as of March 25, 2024, the record date for the Annual Meeting. There were 162,989,650 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on three proposals, each of which is described in more detail in BioMarin's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 9, 2024 (the "Proxy Statement"). Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal 1: Election of Directors

Directors Elected		Vote For		Withheld		Broker Non-Votes
Elizabeth McKee Anderson		143,725,729		9,003,309		10,260,612
Barbara W. Bodem		152,126,450		602,588		10,260,612
Athena Countouriotis, M.D.		152,107,502		621,536		10,260,612
Willard Dere, M.D.		147,153,181		5,575,857		10,260,612
Mark J. Enyedy		152,125,947		603,091		10,260,612
Alexander Hardy		151,780,693		948,345		10,260,612
Elaine J. Heron, Ph.D.		144,192,766		8,536,272		10,260,612
Maykin Ho, Ph.D.		143,813,807		8,915,231		10,260,612
Robert J. Hombach		149,094,947		3,634,091		10,260,612
Richard A. Meier		146,622,137		6,106,901		10,260,612
David E.I. Pyott, M.D. (Hon.)		146,332,496		6,396,542		10,260,612

Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director's death, resignation or removal.

Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm

The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2024, as set forth in the Proxy Statement, received the following votes:

For		Against		Abstain
156,548,552		6,404,458		36,640

Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2024.

Proposal 3: Advisory Vote on the Compensation of Named Executive Officers

The advisory (non-binding)vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes:

For		Against		Abstain		Broker Non-Votes
141,887,490		10,757,670		83,878		10,260,612

Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.